C. (2005). Defective B cell tolerance checkpoints in systemic lupus erythematosus. The Journal of experimental medicine 201, 703-711.

[0825] Zanoni, G., Navone, R., Lunardi, C., Tridente, G., Bason, C., Sivori, S., Beri, R., Dolcino, M., Valletta, E., Corrocher, R., et al. (2006). In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS medicine 3, e358.

[0826] Zehentmeier, S., Roth, K., Cseresnyes, Z., Sercan, O., Horn, K., Niesner, R. A., Chang, H. D., Radbruch, A., and Hauser, A. E. (2014). Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. European journal of immunology 44, 2306-2317.

[0827] Zeiser, R., and Blazar, B. R. (2017). Acute Graft-versus-Host Disease—Biologic Process, Prevention, and Therapy. The New England journal of medicine 377, 2167-2179.

[0828] Zha, B., Huang, X., Lin, J., Liu, J., Hou, Y., and Wu, G. (2014). Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease. Journal of clinical laboratory analysis 28, 249-254.

[0829] Zhang, J., Zhang, W., Leung, P. S., Bowlus, C. L., Dhaliwal, S., Coppel, R. L., Ansari, A. A., Yang, G. X., Wang, J., Kenny, T. P., et al. (2014). Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (Baltimore, Md.) 60, 1708-1716.

[0830] Zhang, X., Lindwall, E., Gauthier, C., Lyman, J., Spencer, N., Alarakhia, A., Fraser, A., Ing, S., Chen, M., Webb-Detiege, T., et al. (2015). Circulating CXCR5+ CD4+ helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus 24, 909-917.

[0831] Zhang, Y., Tech, L., George, L. A., Acs, A., Durrett, R. E., Hess, H., Walker, L. S. K., Tarlinton, D. M., Fletcher, A. L., Hauser, A. E., et al. (2018). Plasma cell output from germinal centers is regulated by signals from Tfh and stromal cells. The Journal of experimental medicine 215, 1227-1243.

[0832] Zhou, Z., Niu, H., Zheng, Y. Y., and Morel, L. (2011). Autoreactive marginal zone B cells enter the follicles and interact with $CD4^+$ T cells in lupus-prone mice. BMC immunology 12, 7.

[0833] Zhu, C., Ma, J., Liu, Y., Tong, J., Tian, J., Chen, J., Tang, X., Xu, H., Lu, L., and Wang, S. (2012). Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. The Journal of clinical endocrinology and metabolism 97, 943-950.

[0834] Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013). Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. Jama 309, 2473-2479.

[0835] Zotos, D., Coquet, J. M., Zhang, Y., Light, A., D'Costa, K., Kallies, A., Corcoran, L. M., Godfrey, D. I., Toellner, K. M., Smyth, M. J., et al. (2010). IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. The Journal of experimental medicine 207, 365-378.

1. (canceled)

2. A method of treatment or prevention of a pathogenic immunoglobulin driven B cell disease with a T cell component in a subject by administering to said subject an effective amount of a compound selected from clozapine, norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof wherein said compound causes mature B cells to be inhibited in said subject.

3. (canceled)

4. The method according to claim **2** to **3** wherein the compound is clozapine or a pharmaceutically acceptable salt or solvate thereof.

5. The method according to claim **2** to **4** wherein the mature B cells are class switched memory B cells.

6. The method according to claim **2** to **4** wherein the mature B cells are plasmablasts.

7. The method according to claim **2** wherein the pathogenic immunoglobulin driven B cell disease with a T cell component is a disease selected from the group consisting of vitiligo, psoriasis, coeliac disease, dermatitis herpetiformis, discoid lupus erythematosus, dermatomyositis, polymyositis, Type 1 diabetes mellitus, autoimmune Addison's disease, multiple sclerosis, interstitial lung disease, Crohn's disease, ulcerative colitis, thyroid autoimmune disease, autoimmune uveitis, primary biliary cirrhosis, primary sclerosing cholangitis, undifferentiated connective tissue disease, autoimmune thrombocytopenic purpura, mixed connective tissue disease, an immune-mediated inflammatory disease (IMID) such as scleroderma, rheumatoid arthritis, Sjogren's disease, and an autoimmune connective tissue disease such as systemic lupus erythematosus.

8. The method according to claim **7** wherein the pathogenic immunoglobulin driven B cell disease with a T cell component is psoriasis, a connective tissue disease such as systemic lupus erythematosus, or an immune-mediated inflammatory disease (IMID) such as scleroderma, rheumatoid arthritis or Sjogren's disease.

9. The method according to claim **2** wherein the pathogenic immunoglobulin driven B cell disease with a T cell component is graft versus host disease.

10. The method according claim **2** wherein the compound has the effect of decreasing CD19 (+) B cells and/or (−) B-plasma cells.

11. A method of treatment or prevention of a pathogenic immunoglobulin driven B cell disease with a T cell component in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound selected from clozapine, norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof; and a pharmaceutically acceptable diluent or carrier, wherein said compound causes mature B cells to be inhibited in said subject.

12. The method according to claim **11** wherein the pharmaceutical composition is administered orally.

13. The method according to claim **11** wherein the pharmaceutical composition is formulated as a liquid or solid, such as a syrup, suspension, emulsion, tablets, capsule or lozenge.

14. The method according to claim **11** wherein the mature B cells are class switched memory B cells.

15. The method according to claim **11** wherein the mature B cells are plasmablasts.

16. A method according to claim **2** wherein the compound is administered in combination with a second or further